Investing.com - (NASDAQ:Mylan) first quarter earnings per share beat estimates.
The pharmaceutical reported a 22% rise in adjusted, diluted Q1 EPS to $0.93 v.s estimate of $0.92.
Revenues were up 24% at $2.72 bn, missing an estimate of $2.84 bn.
Mylan shares were up 3.26% pre-market at $39.25.